Responses of Gut Microbiota and Glucose and Lipid Metabolism to Prebiotics in Genetic Obese and Diet-induced Leptin-resistant Mice
Overview
Authors
Affiliations
Objective: To investigate deep and comprehensive analysis of gut microbial communities and biological parameters after prebiotic administration in obese and diabetic mice.
Research Design And Methods: Genetic (ob/ob) or diet-induced obese and diabetic mice were chronically fed with prebiotic-enriched diet or with a control diet. Extensive gut microbiota analyses, including quantitative PCR, pyrosequencing of the 16S rRNA, and phylogenetic microarrays, were performed in ob/ob mice. The impact of gut microbiota modulation on leptin sensitivity was investigated in diet-induced leptin-resistant mice. Metabolic parameters, gene expression, glucose homeostasis, and enteroendocrine-related L-cell function were documented in both models.
Results: In ob/ob mice, prebiotic feeding decreased Firmicutes and increased Bacteroidetes phyla, but also changed 102 distinct taxa, 16 of which displayed a >10-fold change in abundance. In addition, prebiotics improved glucose tolerance, increased L-cell number and associated parameters (intestinal proglucagon mRNA expression and plasma glucagon-like peptide-1 levels), and reduced fat-mass development, oxidative stress, and low-grade inflammation. In high fat-fed mice, prebiotic treatment improved leptin sensitivity as well as metabolic parameters.
Conclusions: We conclude that specific gut microbiota modulation improves glucose homeostasis, leptin sensitivity, and target enteroendocrine cell activity in obese and diabetic mice. By profiling the gut microbiota, we identified a catalog of putative bacterial targets that may affect host metabolism in obesity and diabetes.
Shen J, Liu H, Wang M, Lu B, Ke K, Wei Y Animals (Basel). 2025; 15(5).
PMID: 40075905 PMC: 11898121. DOI: 10.3390/ani15050622.
Correlation study on gut microbiota and myosteatosis in patients with liver cirrhosis.
Zhao N, Bai J, Li X, Xu G, Fu X, Li J Front Nutr. 2025; 12:1513973.
PMID: 39968394 PMC: 11832399. DOI: 10.3389/fnut.2025.1513973.
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus.
He X, Zhao W, Li P, Zhang Y, Li G, Su H Front Pharmacol. 2025; 15:1483792.
PMID: 39902077 PMC: 11788294. DOI: 10.3389/fphar.2024.1483792.
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions.
Zhao Q, Wu J, Ding Y, Pang Y, Jiang C Life Metab. 2025; 2(6):load032.
PMID: 39872860 PMC: 11749371. DOI: 10.1093/lifemeta/load032.
Calcaterra V, Cena H, Loperfido F, Porri D, Basilico S, Gazzola C Nutrients. 2025; 17(1.
PMID: 39796556 PMC: 11722901. DOI: 10.3390/nu17010123.